What question did this study set out to answer?

To evaluate Time in Therapeutic Range (TTR) among patients receiving warfarin for non-valvular atrial fibrillation at a cardiovascular referral center.

January 1, 2016JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCHOpen Access

Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study

View Full Paper

Ask AI

Bookmark

Population

470 patients with non-valvular atrial fibrillation receiving treatment with warfarin, mean age 58.0±14.2…

Design

Cross-sectional

Follow-up

6 months

Authors

BFBahram Fariborz FarsadIran University of Medical Sciences

Discussion

Member takes

Implication

Suboptimal TTR in this Iranian cohort signals need for better monitoring; leaves open whether targeted interventions improve outcomes in similar settings.

Key Points

To evaluate Time in Therapeutic Range (TTR) among patients receiving warfarin for non-valvular atrial fibrillation at a cardiovascular referral center.
Conducted a cross-sectional study over 6 months enrolling consecutive patients presenting for routine INR testing at Shaheed Rajaie Hospital in Tehran, Iran (N=470).
Calculated TTR using the Rosendaal method across 1,450 total INR measurements and evaluated demographic and medication predictors.
The overall mean TTR was 54.9±11.9%, with 37.3% categorized as good control (TTR > 70%), 24.6% intermediate control (50–70%), and 38.1% poor control (TTR < 50%).
Using more than four concurrent medications was a significant predictor of poor anticoagulation control (OR = 2.06; 95% CI, 1.87 to 2.23).

Structured PICO

Population

470 patients with non-valvular atrial fibrillation receiving treatment with warfarin, mean age 58.0±14.2 years, 60.2% women, presenting to a referral center in Tehran, Iran.

Intervention

Warfarin therapy (observational assessment of anticoagulation control)

Outcome

Time in Therapeutic Range (TTR) assessed by the Rosendaal methodsurrogate

The quality of warfarin anticoagulation in Iranian patients with non-valvular atrial fibrillation is suboptimal (mean TTR 54.9%), highlighting a need for improved management strategies or alternative therapies.

Cite This Study

Bahram Fariborz Farsad (2016) studied this question.

synapsesocial.com/papers/6a709bc275498292b70a0eb3 https://doi.org/10.7860/jcdr/2016/21955.8457

View Full Paper

Ask AI

Bookmark

Implication

Suboptimal TTR in this Iranian cohort signals need for better monitoring; leaves open whether targeted interventions improve outcomes in similar settings.

Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider